AGIO
AGIO
Positions held
Your positionsAGIO isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | — | Beta | — | Dividend yield | — |
| Revenue growth | — | Earnings growth | — | Gross margin | — | Operating margin | — |
| Profit margin | — | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | — | Free cash flow | — | Analyst recommendation | — | Mean target | — |
| 52w high | — | 52w low | — |
Quarterly
No data yet.
Yearly (6y)
No data yet.
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET
2026-10-06 · AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know
2026-10-02 · Agios' Growth Story Hinges on Mitapivat's Commercial Expansion
2026-09-21 · BofA Securities Adjusts Agios Pharmaceuticals Price Target to $50 From $46, Maintains Buy Rating
2026-09-04 · Revolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue?
2026-07-30 · Agios Pharmaceuticals Inc (AGIO) (Q2 2026) Earnings Call Highlights: Strong Mitapivat Revenue ...
2026-07-30 · Agios Pharmaceuticals Q2 Earnings Call Highlights
2026-07-30 · Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates
2026-07-30 · Agios Pharmaceuticals Q2 Loss Narrows as Revenue Increases
2026-07-30 · Agios Pharmaceuticals: Q2 Earnings Snapshot
2026-07-30 · Agios Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-07-30 · Tebapivat Sickle Cell Setback and Mitapivat Priority Review Could Be A Game Changer For Agios (AGIO)
Price (daily)
Full chart · RSI · MACD · patterns